Literature DB >> 10605022

Conserved MHC class I peptide binding motif between humans and rhesus macaques.

J L Dzuris1, J Sidney, E Appella, R W Chesnut, D I Watkins, A Sette.   

Abstract

Since the onset of the HIV pandemic, the use of nonhuman primate models of infection has increasingly become important. An excellent model to study HIV infection and immunological responses, in particular cell-mediated immune responses, is SIV infection of rhesus macaques. CTL epitopes have been mapped using SIV-infected rhesus macaques, but, to date, a peptide binding motif has been described for only one rhesus class I MHC molecule, Mamu-A*01. Herein, we have established peptide-live cell binding assays for four rhesus MHC class I molecules: Mamu-A*11, -B*03, -B*04, and -B*17. Using such assays, peptide binding motifs have been established for all four of these rhesus MHC class I molecules. With respect to the nature and spacing of crucial anchor positions, the motifs defined for Mamu-B*04 and -B*17 present unique features not previously observed for other primate species. The motifs identified for Mamu-A*11 and -B*03 are very similar to the peptide binding motifs previously described for human HLA-B*44 and -B*27, respectively. Accordingly, naturally processed peptides derived from HLA-B*44 and HLA-B*27 specifically bind Mamu-A*11 and Mamu-B*03, respectively, indicating that conserved MHC class I binding capabilities exist between rhesus macaques and humans. The definition of four rhesus MHC class I-specific motifs expands our ability to accurately detect and quantitate immune responses to MHC class I-restricted epitopes in rhesus macaques and to rationally design peptide epitope-based model vaccine constructs destined for use in nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10605022     DOI: 10.4049/jimmunol.164.1.283

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution.

Authors:  Alessandro Sette; John Sidney; Brian D Livingston; John L Dzuris; Claire Crimi; Christopher M Walker; Scott Southwood; Edward J Collins; Austin L Hughes
Journal:  Immunogenetics       Date:  2003-02-14       Impact factor: 2.846

2.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities.

Authors:  Scott Southwood; Christopher Solomon; Ilka Hoof; Richard Rudersdorf; John Sidney; Bjoern Peters; Angela Wahl; Oriana Hawkins; William Hildebrand; Bianca R Mothé; Alessandro Sette
Journal:  Immunogenetics       Date:  2011-01-28       Impact factor: 2.846

4.  Transcriptionally abundant major histocompatibility complex class I alleles are fundamental to nonhuman primate simian immunodeficiency virus-specific CD8+ T cell responses.

Authors:  Melisa L Budde; Jennifer J Lhost; Benjamin J Burwitz; Ericka A Becker; Charles M Burns; Shelby L O'Connor; Julie A Karl; Roger W Wiseman; Benjamin N Bimber; Guang Lan Zhang; William Hildebrand; Vladimir Brusic; David H O'Connor
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

5.  CD8+ T cell escape mutations in simian immunodeficiency virus SIVmac239 cause fitness defects in vivo, and many revert after transmission.

Authors:  Philip A Mudd; Adam J Ericsen; Andrew D Walsh; Enrique J León; Nancy A Wilson; Nicholas J Maness; Thomas C Friedrich; David I Watkins
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Authors:  Gaia Sciaranghella; Samir K Lakhashe; Mila Ayash-Rashkovsky; Saied Mirshahidi; Nagadenahalli B Siddappa; Francis J Novembre; Vijayakumar Velu; Rama Rao Amara; Chenghui Zhou; Sufen Li; Zhongxia Li; Fred R Frankel; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-11-09       Impact factor: 3.641

7.  A combined prediction strategy increases identification of peptides bound with high affinity and stability to porcine MHC class I molecules SLA-1*04:01, SLA-2*04:01, and SLA-3*04:01.

Authors:  Lasse Eggers Pedersen; Michael Rasmussen; Mikkel Harndahl; Morten Nielsen; Søren Buus; Gregers Jungersen
Journal:  Immunogenetics       Date:  2015-11-14       Impact factor: 2.846

8.  The locus encoding an oligomorphic family of MHC-A alleles (Mane-A*06/Mamu-A*05) is present at high frequency in several macaque species.

Authors:  Bernard A P Lafont; Christopher M McGraw; Sabriya A Stukes; Alicia Buckler-White; Ronald J Plishka; Russell A Byrum; Vanessa M Hirsch; Malcolm A Martin
Journal:  Immunogenetics       Date:  2007-01-26       Impact factor: 2.846

9.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

10.  Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Authors:  J L Dzuris; J Sidney; H Horton; R Correa; D Carter; R W Chesnut; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.